Back to Clinical Trials

Brief Title: Bladder Cancer Longitudinal Biorepository for Development of Novel Therapeutics/Biomarkers

Bladder Cancer Longitudinal Biorepository for Development of Novel Therapeutics/Biomarkers

INTRODUCTION

  • Org Study ID: STUDY00141546
  • Secondary ID: N/A
  • NTC ID: NCT03413982
  • Sponsor: University of Kansas Medical Center

BRIEF SUMMARY

The purpose of this study is to create a registry, which is a "bank" of information about patients who have had similar medical conditions and treatments. The registry will be used by researchers to learn more about long term outcome of patients with bladder cancer, how bladder cancer tissues are related to tumor development, recurrence and survival.

  • Overall Status
    Recruiting
  • Start Date
    November 2, 2017
  • Phase
  • Study Type
    Observational

PRIMARY OUTCOMES

Primary Outcome 1 - Measure: Blood, urine and tissue characteristics of bladder cancer patients

Primary Outcome 1 - Timeframe: 24 months

CONDITION

  • Bladder Cancer

ELIGIBILITY

Inclusion Criteria:
Patients who present to clinic with presumed bladder cancer or have a diagnosis of bladder cancer are eligible to participate

- Patients can participate in any additional research studies during the patients' participation within this protocol.
Exclusion Criteria:
Patients who do not have presumed bladder cancer will not be eligible

Gender: All

Minimum Age: 18 Years

Maximum Age: N/A

Healthy Volunteers: No

OFFICIAL INFORMATION

Name: John Taylor, MD

Role: Principal Investigator

Affiliation: University of Kansas Medical Center

Overall Contact

Name: John Taylor, MD

Phone: 913-588-8721

Email: kglavin@kumc.edu

LOCATION

Facility Status Contact
Facility: University of Kansas Medical Center
Kansas City, Kansas 66160
United States
Status: Recruiting Contact: N/A